Wall Street Zen Downgrades Compass Pathways (NASDAQ:CMPS) to Strong Sell

Compass Pathways (NASDAQ:CMPS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report released on Saturday.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus increased their price objective on Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. UBS Group set a $18.00 target price on Compass Pathways in a report on Thursday, May 7th. Wolfe Research reaffirmed an “outperform” rating on shares of Compass Pathways in a report on Tuesday, July 7th. Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Finally, Wells Fargo & Company assumed coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an “equal weight” rating and a $13.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.36.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $13.54 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. Compass Pathways has a fifty-two week low of $3.97 and a fifty-two week high of $15.40. The stock has a 50 day moving average price of $12.59 and a two-hundred day moving average price of $9.35. The company has a market capitalization of $1.83 billion, a P/E ratio of -2.93 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). Analysts expect that Compass Pathways will post -1.25 earnings per share for the current year.

Institutional Trading of Compass Pathways

Several large investors have recently made changes to their positions in CMPS. EverSource Wealth Advisors LLC grew its position in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways in the fourth quarter valued at approximately $38,000. Parallel Advisors LLC increased its position in Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter worth approximately $41,000. Finally, North Star Investment Management Corp. raised its position in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after purchasing an additional 7,000 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.